Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
1 Introduction Immune checkpoint inhibitors (ICIs), particularly antibodies targeting programmed cell death protein-1 (PD-1), have transformed cancer therapy by restoring antitumor T-cell activity and improving survival across multiple malignancies [1, 2]. However, their increasing clinical use has revealed a spectrum of immune-related adverse events (irAEs), among which cardiovascular toxicities are rare but often severe and potentially fatal [3, 4].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
